Who
Thomas J. Schuetz
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Compass Therapeutics; Director, Audentes Therapeutics; Director, Relypsa.
In numbers
- Trades disclosed
- 78
- Buys
- 24
- Sells
- 1
- Bought
- $2.1M
- Sold
- $35K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 19 Jun 2014
- Last trade
- 8 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Feb 2026filed 10 Feb 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $239K36,687 at $6.52 | filing |
| 8 Feb 2026filed 10 Feb 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $239K36,687 at $6.52 | filing |
| 9 Jan 2026filed 12 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $250K46,777 at $5.35 | filing |
| 9 Jan 2026filed 12 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $250K46,777 at $5.35 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.3M250,000 at $5.17 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.3M250,000 at $5.17 | filing |
| 16 Nov 2025filed 18 Nov 2025 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $213K44,025 at $4.83 | filing |
| 27 May 2025filed 27 May 2025 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $21K10,000 at $2.11 | filing |
| 11 Feb 2025filed 13 Feb 2025 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 8 Feb 2025filed 11 Feb 2025 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $146K41,687 at $3.50 | filing |
| 9 Jan 2025filed 13 Jan 2025 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $108K58,054 at $1.86 | filing |
| 8 Feb 2024filed 9 Feb 2024 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $65K44,782 at $1.45 | filing |
| 9 Jan 2024filed 10 Jan 2024 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —637,500 at $0.00 | filing |
| 9 Jan 2024filed 10 Jan 2024 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.2M637,500 at $1.93 | filing |
| 17 Nov 2023filed 21 Nov 2023 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code F | $66K44,025 at $1.50 | filing |
| 10 Mar 2023filed 10 Mar 2023 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K10,000 at $3.37 | filing |
| 27 Feb 2023filed 27 Feb 2023 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $80K20,000 at $3.98 | filing |
| 15 Feb 2023filed 15 Feb 2023 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $77K20,000 at $3.86 | filing |
News
Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21CMPX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Thomas J. Schuetz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.